March 12, 2025

Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway

Research and Publications

The Hippo Pathway and Human Cancer

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics